Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
OM Stock Forecast 2026-2027
$4.31
Current Price
$79.90M
Market Cap
Buy 2
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to OM Price Targets
+132.0%
To High Target of $10.00
+85.6%
To Median Target of $8.00
+62.4%
To Low Target of $7.00
OM Price Momentum
-8.1%
1 Week Change
+18.7%
1 Month Change
-78.9%
1 Year Change
+16.2%
Year-to-Date Change
-79.8%
From 52W High of $21.36
+43.7%
From 52W Low of $3.00
📊 TOP ANALYST CALLS
Did OM Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Outset Medical is one of their latest high-conviction picks.
Latest OM Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, OM has a bullish consensus with a median price target of $8.00 (ranging from $7.00 to $10.00). The overall analyst rating is Strong Buy (8.7/10). Currently trading at $4.31, the median forecast implies a 85.6% upside. This outlook is supported by 2 Buy, 1 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
OM Analyst Ratings
2
Buy
1
Hold
0
Sell
OM Price Target Range
Low
$7.00
Average
$8.00
High
$10.00
Current: $4.31
Latest OM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for OM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 12, 2026 | BTIG | Marie Thibault | Buy | Maintains | $15.00 |
| Jan 7, 2026 | Stifel | Buy | Maintains | $N/A | |
| Dec 16, 2025 | BTIG | Buy | Reiterates | $N/A | |
| Nov 11, 2025 | Stifel | Buy | Maintains | $N/A | |
| Nov 11, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Nov 11, 2025 | BTIG | Buy | Maintains | $N/A | |
| Aug 19, 2025 | RBC Capital | Sector Perform | Reiterates | $N/A | |
| Aug 7, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| May 21, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| May 8, 2025 | RBC Capital | Sector Perform | Maintains | $N/A | |
| Jan 7, 2025 | RBC Capital | Sector Perform | Reiterates | $N/A | |
| Aug 8, 2024 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Aug 8, 2024 | TD Cowen | Buy | Maintains | $N/A | |
| Jun 21, 2024 | RBC Capital | Outperform | Upgrade | $N/A | |
| Apr 8, 2024 | BTIG | Buy | Initiates | $N/A | |
| Jan 12, 2024 | RBC Capital | Sector Perform | Downgrade | $N/A | |
| Dec 4, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Nov 14, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| Oct 13, 2023 | RBC Capital | Outperform | Maintains | $N/A | |
| Oct 13, 2023 | Stifel | Buy | Maintains | $N/A |
Outset Medical Inc. (OM) Competitors
The following stocks are similar to Outset Medical based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Outset Medical Inc. (OM) Financial Data
Outset Medical Inc. has a market capitalization of $79.90M with a P/E ratio of -0.8x. The company generates $117.59M in trailing twelve-month revenue with a -63.7% profit margin.
Revenue growth is -6.3% quarter-over-quarter, while maintaining an operating margin of -60.7% and return on equity of -53.2%.
Valuation Metrics
Market Cap
$79.90M
Enterprise Value
$24.80M
P/E Ratio
-0.8x
PEG Ratio
0.0x
Price/Sales
0.7x
Growth & Margins
Revenue Growth (YoY)
-6.3%
Gross Margin
+43.4%
Operating Margin
-60.7%
Net Margin
-63.7%
EPS Growth
-6.3%
Financial Health
Cash/Price Ratio
+196.1%
Current Ratio
6.3x
Debt/Equity
91.0x
ROE
-53.2%
ROA
-15.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Outset Medical Inc. (OM) Business Model
About Outset Medical Inc.
What They Do
Develops innovative dialysis solutions.
Business Model
Outset Medical generates revenue through the development and commercialization of its flagship product, the Tablo Hemodialysis System. This system is designed for both medical facilities and home use, integrating essential functions like water purification and dialysate production into a single device, which enhances the efficiency and accessibility of dialysis treatments.
Additional Information
The company is headquartered in the United States and is focused on transforming dialysis care to improve patient quality of life. Their innovative approach is positioned to meet the increasing demand for effective renal care solutions in the healthcare market.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
310
CEO
Ms. Leslie L. Trigg
Country
United States
IPO Year
2020
Website
www.outsetmedical.comOutset Medical Inc. (OM) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
DaVita Expands Comprehensive Kidney Care Through Dialysis Services
DVA expands kidney-care reach with integrated CKD/ESKD coordination and 2026 AI scheduling tech to boost dialysis efficiency.
Jun 04, 2026
By Debanjana Dey
Analyst Blog
Latest News
Quick Summary
OM Pharma announced a significant multi-country real-world evidence study on Broncho Vaxom® (OM 85) for respiratory tract infection prevention, presented at EAACI 2026.
Why It Matters
OM Pharma's study on Broncho Vaxom® may indicate strong efficacy in respiratory tract infection prevention, potentially boosting sales and market confidence, impacting stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Osisko Metals announced initial results from its 2026 drill program at the Gaspé Copper Project in Québec, with five drills active and two more starting this month.
Why It Matters
The announcement of active drilling at the Gaspé Copper Project suggests potential resource discoveries, which could enhance Osisko Metals' value and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Shareholders are encouraged to contact the firm promptly regarding potential legal rights, with services offered on a contingent fee basis, meaning no upfront costs.
Why It Matters
The notice indicates potential legal issues affecting shareholders, which could impact stock value and investor confidence, prompting immediate attention to rights and claims.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Osisko Metals Inc. held its annual shareholder meeting on May 28, 2026, with 475,369,374 shares represented, accounting for 64.4% of total shares outstanding.
Why It Matters
High shareholder participation at Osisko's annual meeting signals strong investor engagement, which could influence stock stability and market confidence in the company's future performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Osisko Metals filed a NI 43-101 Technical Report for the Gaspé Copper Project, updating the mineral resource estimate for the Copper Mountain Deposit in Quebec, dated May 28, 2026.
Why It Matters
The filing of the technical report indicates a potential increase in the mineral resource estimate, which could enhance Osisko Metals' valuation and attract investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Outset Medical, Inc. announced the approval of equity awards for two new non-executive employees as part of its Inducement Plan, in compliance with Nasdaq rules.
Why It Matters
Outset Medical's equity awards may signal growth and attract talent, potentially enhancing innovation and competitive positioning, impacting future profitability and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About OM Stock
What is Outset Medical Inc.'s (OM) stock forecast for 2026?
Based on our analysis of 2 Wall Street analysts, Outset Medical Inc. (OM) has a median price target of $8.00. The highest price target is $10.00 and the lowest is $7.00.
Is OM stock a good investment in 2026?
According to current analyst ratings, OM has 2 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for OM stock?
Wall Street analysts predict OM stock could reach $8.00 in the next 12 months. This represents a 85.6% increase from the current price of $4.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Outset Medical Inc.'s business model?
Outset Medical generates revenue through the development and commercialization of its flagship product, the Tablo Hemodialysis System. This system is designed for both medical facilities and home use, integrating essential functions like water purification and dialysate production into a single device, which enhances the efficiency and accessibility of dialysis treatments.
What is the highest forecasted price for OM Outset Medical Inc.?
The highest price target for OM is $10.00 from at , which represents a 132.0% increase from the current price of $4.31.
What is the lowest forecasted price for OM Outset Medical Inc.?
The lowest price target for OM is $7.00 from at , which represents a 62.4% increase from the current price of $4.31.
What is the overall OM consensus from analysts for Outset Medical Inc.?
The overall analyst consensus for OM is bullish. Out of 2 Wall Street analysts, 2 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are OM stock price projections?
Stock price projections, including those for Outset Medical Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 11:40 AM UTC